{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T00:43:55Z","timestamp":1793580235138,"version":"4.5.0"},"reference-count":114,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Forschung, Technologie und Raumfahrt","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["70117182"],"award-info":[{"award-number":["70117182"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["SFB-TRR 338\/1 2021\\u2013452881907"],"award-info":[{"award-number":["SFB-TRR 338\/1 2021\\u2013452881907"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["CoG 101124203"],"award-info":[{"award-number":["CoG 101124203"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["101100460"],"award-info":[{"award-number":["101100460"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["756017"],"award-info":[{"award-number":["756017"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008848","name":"Elite Network of Bavaria","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008848","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008672","name":"Wilhelm Sander-Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008672","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015754","name":"Stiftung der Deutschen Wirtschaft gGmbH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015754","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002745","name":"Bavarian Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002745","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010138","name":"Fritz Bender Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010138","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["955575"],"award-info":[{"award-number":["955575"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021372","name":"HW & J. Hector Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021372","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004038","name":"Jung-Stiftung fur Wissenschaft und Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005677","name":"Deutsche Jos\u00e9 Carreras Leuk\u00e4mie-Stiftung eV","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100029989","name":"California Association of Realtors","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100029989","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005722","name":"Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005722","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005190","name":"Melanoma Research Alliance","doi-asserted-by":"publisher","award":["409510"],"award-info":[{"award-number":["409510"]}],"id":[{"id":"10.13039\/100005190","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018693","name":"HORIZON EUROPE Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["KO5055-2-1"],"award-info":[{"award-number":["KO5055-2-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["KO5055\/3-1"],"award-info":[{"award-number":["KO5055\/3-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Cell Research"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.bbamcr.2026.120115","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T16:47:21Z","timestamp":1769186841000},"page":"120115","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["The role of cytokines in cytokine release syndrome (CRS) after CAR T cell therapy"],"prefix":"10.1016","volume":"1873","author":[{"given":"Kathrin","family":"Gabriel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Heinzerling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louisa","family":"von Baumgarten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Subklewe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Kobold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbamcr.2026.120115_bb0005","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0010","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbamcr.2026.120115_bb0015","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1158\/1078-0432.CCR-07-0674","article-title":"Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts","volume":"13","author":"Brentjens","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0020","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene Ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0025","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2406526","article-title":"Obecabtagene Autoleucel in adults with B-cell acute lymphoblastic leukemia","volume":"391","author":"Roddie","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0030","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","article-title":"Current understanding and management of CAR T cell-associated toxicities","volume":"21","author":"Brudno","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0035","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005930","article-title":"CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia","volume":"5","author":"Brentjens","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0040","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00281-024-01013-w","article-title":"Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy","volume":"46","author":"Hughes","year":"2024","journal-title":"Semin. Immunopathol."},{"issue":"191","key":"10.1016\/j.bbamcr.2026.120115_bb0045","article-title":"Practical guidelines for the management of adverse events of the T cell engager bispecific tebentafusp","volume":"1990","author":"Hassel","year":"2023","journal-title":"Eur. J. Cancer Oxf. Engl."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0050","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.807050","article-title":"Cytokine release syndrome in cancer patients receiving immune checkpoint inhibitors: a case series of 25 patients and review of the literature","volume":"13","author":"Tay","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0055","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy \u2014 assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0060","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0065","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0070","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bbamcr.2026.120115_bb0075","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bbamcr.2026.120115_bb0080","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1200\/JCO.20.01616","article-title":"How I manage: pathophysiology and Management of Toxicity of chimeric antigen receptor T-cell therapies","volume":"39","author":"Reagan","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0085","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant"},{"key":"10.1016\/j.bbamcr.2026.120115_bb0090","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1038\/s41591-024-03084-6","article-title":"A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy","volume":"30","author":"Cordas Dos Santos","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0095","doi-asserted-by":"crossref","first-page":"9228","DOI":"10.1002\/cam4.5665","article-title":"Procalcitonin as a biomarker for predicting bacterial infection in chimeric antigen receptor T-cell therapy recipients","volume":"12","author":"Powell","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0100","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.3389\/fimmu.2020.01973","article-title":"Neurotoxicity and cytokine release syndrome after chimeric antigen receptor T cell therapy: insights into mechanisms and novel therapies","volume":"11","author":"Siegler","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0105","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41409-020-01134-4","article-title":"Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL","volume":"56","author":"Sheth","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0110","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0115","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor\u2013modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bbamcr.2026.120115_bb0120","article-title":"A major role for CD4+ T cells in driving cytokine release syndrome during CAR T cell therapy","volume":"4","author":"Boulch","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0125","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0130","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0135","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.bbamcr.2026.120115_bb0140","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","article-title":"Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Locke","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0145","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.omto.2020.06.016","article-title":"Efficacy and safety of CD28- or 4-1BB-based CD19 CAR-T cells in B cell acute lymphoblastic leukemia","volume":"18","author":"Zhao","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.bbamcr.2026.120115_bb0150","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1038\/s41591-022-01969-y","article-title":"A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR t cells in relapsed or refractory diffuse large B cell lymphoma","volume":"28","author":"Bachy","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0155","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1182\/bloodadvances.2020003885","article-title":"Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells","volume":"5","author":"Pennisi","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0160","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s00277-024-05617-y","article-title":"Modified EASIX scores predict severe CRS\/ICANS in patients with acute myeloid leukemia following CLL1 CAR-T cell therapy","volume":"103","author":"Zhao","year":"2024","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0165","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1182\/bloodadvances.2024014027","article-title":"EASIX and m-EASIX predict CRS and ICANS in pediatric and AYA patients after CD19-CAR T-cell therapy","volume":"9","author":"Zandaki","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0170","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1016\/j.ymthe.2024.03.030","article-title":"Need for standardization of cytokine profiling in CAR T cell therapy","volume":"32","author":"Biery","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0175","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aar3451","article-title":"Tumor immune evasion arises through loss of TNF sensitivity","volume":"3","author":"Kearney","year":"2018","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0180","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/nri1184","article-title":"Signalling pathways of the TNF superfamily: a double-edged sword","volume":"3","author":"Aggarwal","year":"2003","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0185","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s40364-020-00228-x","article-title":"Roles of IFN-\u03b3 in tumor progression and regression: a review","volume":"8","author":"Jorgovanovic","year":"2020","journal-title":"Biomark. Res."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0190","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.immuni.2010.08.004","article-title":"Interleukin-2 receptor signaling: at the interface between tolerance and immunity","volume":"33","author":"Malek","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.bbamcr.2026.120115_bb0195","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aax7969","article-title":"Gasdermin E\u2013mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome","volume":"5","author":"Liu","year":"2020","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0200","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaz7548","article-title":"Granzyme a from cytotoxic lymphocytes cleaves GSDMB to trigger pyroptosis in target cells","volume":"368","author":"Zhou","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.bbamcr.2026.120115_bb0205","article-title":"Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies","volume":"40","author":"Xiao","year":"2021","journal-title":"J. Exp. Clin. Cancer Res. CR"},{"key":"10.1016\/j.bbamcr.2026.120115_bb0210","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41577-019-0228-2","article-title":"The gasdermins, a protein family executing cell death and inflammation","volume":"20","author":"Broz","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0215","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41577-019-0215-7","article-title":"DAMP-sensing receptors in sterile inflammation and inflammatory diseases","volume":"20","author":"Gong","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0220","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.tibs.2016.10.004","article-title":"Pyroptosis: Gasdermin-mediated programmed necrotic cell death","volume":"42","author":"Shi","year":"2017","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0225","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.922212","article-title":"Investigation of the risk factors to predict cytokine release syndrome in relapsed or refractory B-cell acute lymphoblastic leukemia patients receiving IL-6 knocking down anti-CD19 chimeric antigen receptor T-cell therapy","volume":"13","author":"Gong","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0230","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-43617-5","article-title":"Activation of toll-like receptor 2 (TLR2) induces interleukin-6 trans-signaling","volume":"9","author":"Flynn","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0235","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001466","article-title":"Blockade of AIM2 inflammasome or \u03b11-AR ameliorates IL-1\u03b2 release and macrophage-mediated immunosuppression induced by CAR-T treatment","volume":"9","author":"Liu","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bbamcr.2026.120115_bb0240","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.349","article-title":"Signaling pathways in macrophages: molecular mechanisms and therapeutic targets","volume":"4","author":"Li","year":"2023","journal-title":"MedComm"},{"key":"10.1016\/j.bbamcr.2026.120115_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2021.101523","article-title":"Targeting GM-CSF in inflammatory and autoimmune disorders","volume":"54","author":"Achuthan","year":"2021","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0250","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/ni828","article-title":"Sensitization of IFN-gamma Jak-STAT signaling during macrophage activation","volume":"3","author":"Hu","year":"2002","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0255","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nri3581","article-title":"Regulation of type I interferon responses","volume":"14","author":"Ivashkiv","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0260","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1189\/jlb.71.3.511","article-title":"Granulocyte-macrophage colony-stimulating factor (GM-CSF)-induced STAT5 activation and target-gene expression during human monocyte\/macrophage differentiation","volume":"71","author":"Lehtonen","year":"2002","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0265","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20190945","article-title":"GM-CSF in inflammation","volume":"217","author":"Hamilton","year":"2020","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0270","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.3389\/fimmu.2018.01849","article-title":"Tumor necrosis factor receptor-associated factor regulation of nuclear factor \u03baB and mitogen-activated protein kinase pathways","volume":"9","author":"Shi","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0275","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1126\/science.1071924","article-title":"TNF-R1 signaling: a beautiful pathway","volume":"296","author":"Chen","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.bbamcr.2026.120115_bb0280","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41577-022-00792-3","article-title":"Death by TNF: a road to inflammation","volume":"23","author":"van Loo","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0285","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.smim.2009.05.011","article-title":"Macrophage CD40 signaling: a pivotal regulator of disease protection and pathogenesis","volume":"21","author":"Suttles","year":"2009","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0290","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1146\/annurev.immunol.021908.132612","article-title":"Immunological and inflammatory functions of the interleukin-1 family","volume":"27","author":"Dinarello","year":"2009","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0295","article-title":"Interleukin-1 (IL-1) pathway","volume":"3","author":"Weber","year":"2010","journal-title":"Sci. Signal."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0300","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.3389\/fimmu.2019.01426","article-title":"IL-1 family cytokine regulation of vascular permeability and angiogenesis","volume":"10","author":"Fahey","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2020.100838","article-title":"Successful application of anti-CD19 CAR-T therapy with IL-6 knocking down to patients with central nervous system B-cell acute lymphocytic leukemia","volume":"13","author":"Chen","year":"2020","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0310","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0315","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.coi.2015.02.008","article-title":"The IL-6\/gp130\/STAT3 signaling axis: recent advances towards specific inhibition","volume":"34","author":"Garbers","year":"2015","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0320","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/ni.3153","article-title":"IL-6 as a keystone cytokine in health and disease","volume":"16","author":"Hunter","year":"2015","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0325","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1172\/JCI57158","article-title":"Therapeutic strategies for the clinical blockade of IL-6\/gp130 signaling","volume":"121","author":"Jones","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0330","doi-asserted-by":"crossref","DOI":"10.1186\/s12964-018-0268-4","article-title":"Activation of the JAK\/STAT3 and PI3K\/AKT pathways are crucial for IL-6 trans-signaling-mediated pro-inflammatory response in human vascular endothelial cells","volume":"16","author":"Zegeye","year":"2018","journal-title":"Cell Commun. Signal. CCS"},{"key":"10.1016\/j.bbamcr.2026.120115_bb0335","doi-asserted-by":"crossref","first-page":"959","DOI":"10.2217\/imt-2016-0020","article-title":"Immunotherapeutic implications of IL-6 blockade for cytokine storm","volume":"8","author":"Tanaka","year":"2016","journal-title":"Immunotherapy"},{"key":"10.1016\/j.bbamcr.2026.120115_bb0340","doi-asserted-by":"crossref","first-page":"22351","DOI":"10.1073\/pnas.2010229117","article-title":"IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome","volume":"117","author":"Kang","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbamcr.2026.120115_bb0345","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf6812","article-title":"Dysregulation of angiopoietin-1 plays a mechanistic role in the pathogenesis of cerebral malaria","volume":"8","author":"Higgins","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0350","doi-asserted-by":"crossref","first-page":"4150","DOI":"10.1182\/blood-2003-10-3685","article-title":"The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies","volume":"103","author":"Fiedler","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbamcr.2026.120115_bb0355","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/jth.14322","article-title":"Exocytosis of Weibel-Palade bodies: how to unpack a vascular emergency kit","volume":"17","author":"Schillemans","year":"2019","journal-title":"J. Thromb. Haemost. JTH"},{"key":"10.1016\/j.bbamcr.2026.120115_bb0360","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood\u2013brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0365","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.immuni.2009.05.012","article-title":"Interleukin-10 production by Th1 cells requires Interleukin-12-induced STAT4 transcription factor and ERK MAP kinase activation by high antigen dose","volume":"31","author":"Saraiva","year":"2009","journal-title":"Immunity"},{"key":"10.1016\/j.bbamcr.2026.120115_bb0370","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20190418","article-title":"Biology and therapeutic potential of interleukin-10","volume":"217","author":"Saraiva","year":"2020","journal-title":"J. Exp. Med."},{"issue":"1950","key":"10.1016\/j.bbamcr.2026.120115_bb0375","first-page":"3","article-title":"Attracting attention: discovery of IL-8\/CXCL8 and the birth of the chemokine field","volume":"202","author":"Moore","year":"2019","journal-title":"J. Immunol. Baltim. Md"},{"key":"10.1016\/j.bbamcr.2026.120115_bb0380","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1089\/jir.2008.0027","article-title":"Monocyte chemoattractant protein-1 (MCP-1): an overview","volume":"29","author":"Deshmane","year":"2009","journal-title":"J. Interferon Cytokine Res. Off. J. Int. Soc. Interferon Cytokine Res."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0385","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/icb.2010.158","article-title":"CXCR3 ligands: redundant, collaborative and antagonistic functions","volume":"89","author":"Groom","year":"2011","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0390","article-title":"Therapeutic potential of TNF\u03b1 and IL1\u03b2 blockade for CRS\/ICANS in CAR-T therapy via ameliorating endothelial activation","volume":"12","author":"Chen","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0395","doi-asserted-by":"crossref","DOI":"10.1186\/s40164-021-00209-2","article-title":"Etanercept as a new therapeutic option for cytokine release syndrome following chimeric antigen receptor T cell therapy","volume":"10","author":"Zhang","year":"2021","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0400","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2018-10-881722","article-title":"GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts","volume":"133","author":"Sterner","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.bbamcr.2026.120115_bb0405","doi-asserted-by":"crossref","first-page":"5430","DOI":"10.1074\/jbc.AC119.007558","article-title":"Granulocyte\u2013macrophage colony-stimulating factor inactivation in CAR T-cells prevents monocyte-dependent release of key cytokine release syndrome mediators","volume":"294","author":"Sachdeva","year":"2019","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0410","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.21.01992","article-title":"Management of Immune-Related Adverse Events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline","volume":"39","author":"Santomasso","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0415","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1080\/1744666X.2019.1629904","article-title":"Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome","volume":"15","author":"Kotch","year":"2019","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0420","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1182\/blood.2019001463","article-title":"Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy","volume":"134","author":"Gardner","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.bbamcr.2026.120115_bb0425","doi-asserted-by":"crossref","first-page":"429.e1","DOI":"10.1016\/j.jtct.2023.03.019","article-title":"Impact of preemptive use of tocilizumab on chimeric antigen receptor T cell outcomes in non-Hodgkin lymphoma","volume":"29","author":"De Philippis","year":"2023","journal-title":"Transplant. Cell. Ther."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0430","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1002\/cncr.35316","article-title":"Impact of tocilizumab on anti-CD19 chimeric antigen receptor T-cell therapy in B-cell acute lymphoblastic leukemia","volume":"130","author":"Wang","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.bbamcr.2026.120115_bb0435","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1200\/JCO.20.02477","article-title":"Risk-adapted preemptive tocilizumab to prevent severe cytokine release syndrome after CTL019 for pediatric B-cell acute lymphoblastic leukemia: a prospective clinical trial","volume":"39","author":"Kadauke","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0440","doi-asserted-by":"crossref","first-page":"477.e1","DOI":"10.1016\/j.jtct.2021.03.004","article-title":"Early time-to-tocilizumab after B cell maturation antigen-directed chimeric antigen receptor T cell therapy in myeloma","volume":"27","author":"Banerjee","year":"2021","journal-title":"Transplant. Cell. Ther."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0445","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1182\/blood.2020008865","article-title":"Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma","volume":"137","author":"Strati","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.bbamcr.2026.120115_bb0450","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-020-0280-y","article-title":"Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia","volume":"10","author":"Liu","year":"2020","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0455","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/bjh.17527","article-title":"Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma","volume":"194","author":"Oluwole","year":"2021","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0460","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1080\/10428194.2023.2240920","article-title":"Impact of corticosteroids on efficacy of BCMA targeted CAR-T therapy in multiple myeloma","volume":"64","author":"Duvalyan","year":"2023","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.bbamcr.2026.120115_bb0465","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.jtct.2023.04.001","article-title":"Anakinra for refractory cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T cell therapy","volume":"29","author":"Gazeau","year":"2023","journal-title":"Transplant. Cell. Ther."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0470","doi-asserted-by":"crossref","first-page":"5073","DOI":"10.1182\/blood-2022-169809","article-title":"Siltuximab for first-line treatment of cytokine release syndrome: a response to the National Shortage of tocilizumab","volume":"140","author":"Patel","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.bbamcr.2026.120115_bb0475","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2024-207963","article-title":"Treatment with siltuximab for short term complications after chimeric antigen receptor T-cell therapy: a multicenter retrospective analysis","volume":"144","author":"Sanchez-Pina","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.bbamcr.2026.120115_bb0480","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-38723-y","article-title":"Neutralizing IFN\u03b3 improves safety without compromising efficacy of CAR-T cell therapy in B-cell malignancies","volume":"14","author":"Manni","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0485","doi-asserted-by":"crossref","first-page":"5603","DOI":"10.1182\/bloodadvances.2023010712","article-title":"Emapalumab for the treatment of refractory cytokine release syndrome in pediatric patients","volume":"7","author":"Schuelke","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0490","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1158\/2643-3230.BCD-21-0181","article-title":"Blockade or deletion of IFN\u03b3 reduces macrophage activation without compromising CAR T-cell function in hematologic malignancies","volume":"3","author":"Bailey","year":"2022","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0495","doi-asserted-by":"crossref","first-page":"10318","DOI":"10.1182\/blood-2022-167688","article-title":"ZUMA-19: a phase 1\/2 study of axicabtagene ciloleucel plus lenzilumab in patients with relapsed or refractory large B-cell lymphoma","volume":"140","author":"Oluwole","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.bbamcr.2026.120115_bb0500","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jcrc.2020.02.010","article-title":"Extracorporeal cytokine removal in severe CAR-T cell associated cytokine release syndrome","volume":"57","author":"Stahl","year":"2020","journal-title":"J. Crit. Care"},{"key":"10.1016\/j.bbamcr.2026.120115_bb0505","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau5907","article-title":"The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for CAR T cells","volume":"11","author":"Mestermann","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0510","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.bbmt.2016.12.003","article-title":"Ruxolitinib prevents cytokine release syndrome after CART cell therapy without impairing the anti-tumor effect in a xenograft model","volume":"23","author":"Kenderian","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0515","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1111\/jcmm.16176","article-title":"Ruxolitinib mitigates steroid-refractory CRS during CAR T therapy","volume":"25","author":"Pan","year":"2021","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0520","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1182\/blood.2023021306","article-title":"CAR T cells and time-limited ibrutinib as treatment for relapsed\/refractory mantle cell lymphoma: the phase 2 TARMAC study","volume":"143","author":"Minson","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.bbamcr.2026.120115_bb0525","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/leu.2016.262","article-title":"Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms","volume":"31","author":"Ruella","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.bbamcr.2026.120115_bb0530","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s11523-025-01133-9","article-title":"Leveraging the immunomodulatory potential of Ibrutinib for improved outcomes of T cell-mediated therapies of B cell malignancies: a narrative review","volume":"20","author":"Miklos","year":"2025","journal-title":"Target. Oncol."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0535","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005956","article-title":"Dasatinib for treatment of CAR T-cell therapy-related complications","volume":"10","author":"Baur","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bbamcr.2026.120115_bb0540","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-020-01301-7","article-title":"Targeting CDK7 suppresses super enhancer-linked inflammatory genes and alleviates CAR T cell-induced cytokine release syndrome","volume":"20","author":"Wei","year":"2021","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbamcr.2026.120115_bb0545","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.114577","article-title":"Mitochondrial uncoupler BAM15 enhances the function of CD7CAR-TCD7\u2212 cells and reduces the release of cytokines for the therapy of T-cell malignancies","volume":"155","author":"Ma","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0550","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.coi.2021.07.002","article-title":"Safety switches for adoptive cell therapy","volume":"74","author":"Sahillioglu","year":"2022","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0555","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","article-title":"Inducible apoptosis as a safety switch for adoptive cell therapy","volume":"365","author":"Di Stasi","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0560","doi-asserted-by":"crossref","DOI":"10.3390\/cells12212581","article-title":"Cell-Based Models of \u2018Cytokine Release Syndrome\u2019 Endorse CD40L and Granulocyte\u2013Macrophage Colony-Stimulating Factor Knockout in Chimeric Antigen Receptor T Cells as Mitigation Strategy","volume":"12","author":"Dibas","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.bbamcr.2026.120115_bb0565","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1182\/bloodadvances.2019001287","article-title":"Chimeric antigen receptor\u2013T cells with cytokine neutralizing capacity","volume":"4","author":"Tan","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.bbamcr.2026.120115_bb0570","doi-asserted-by":"crossref","DOI":"10.1038\/s41421-021-00299-6","article-title":"Chimeric antigen receptor T cells self-neutralizing IL6 storm in patients with hematologic malignancy","volume":"7","author":"Xue","year":"2021","journal-title":"Cell Discov."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Cell Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016748892600011X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016748892600011X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T08:19:54Z","timestamp":1781943594000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016748892600011X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":114,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S016748892600011X"],"URL":"https:\/\/doi.org\/10.1016\/j.bbamcr.2026.120115","relation":{},"ISSN":["0167-4889"],"issn-type":[{"value":"0167-4889","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of cytokines in cytokine release syndrome (CRS) after CAR T cell therapy","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Molecular Cell Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbamcr.2026.120115","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"120115"}}